Dog · Canis lupus familiaris · typical adult weight 2.00–80.00 kg
Hydroxyurea is dosed at 50–60 mg/kg PO q24h initially, then taper to every other day in dogs, per Withrow & MacEwen's Small Animal Clinical Oncology, 5th Ed (2013) - held; rule cites 6th Ed - corpus p.186 (printed p.172), Ch.11; corroborated by Plumb's Veterinary Drug Handbook 10th Ed, corpus p.656 (printed p.629), DOGS: 30-60 mg/kg PO once daily — Plumb's 10th ed (held) printed p.628, Hydroxyurea monograph; page located 2026-08-05 from the book's own running heads, verified to name the drug in its body text. — SOURCE EDITION: Plumb's Veterinary Drug Handbook — ISBN 9781394172207, https://openlibrary.org/isbn/9781394172207; Withrow and MacEwen's Small Animal Clinical Oncology — ISBN 9781437723625, https://openlibrary.org/isbn/9781437723625. Hydroxyurea is used in dogs for Polycythemia vera / chronic myelogenous leukaemia. Routes documented in dogs: PO. A typical adult dog weighs 2.00–80.00 kg. ExoticRx lists 1 cited dose rule for Hydroxyurea in dogs, drawn from published veterinary references. Verify against current literature before clinical use.
US trade names: Hydrea, Droxia
| Route | Dose | Frequency | Duration | Indication | Evidence | Source |
|---|---|---|---|---|---|---|
| PO | 50–60 mg/kg | q24h initially, then taper to every other day | Chronic use; titrate based on CBC | Polycythemia vera / chronic myelogenous leukaemia | Weak | Withrow & MacEwen's Small Animal Clinical Oncology, 5th Ed (2013) - held; rule cites 6th Ed - corpus p.186 (printed p.172), Ch.11; corroborated by Plumb's Veterinary Drug Handbook 10th Ed, corpus p.656 (printed p.629), DOGS: 30-60 mg/kg PO once daily — Plumb's 10th ed (held) printed p.628, Hydroxyurea monograph; page located 2026-08-05 from the book's own running heads, verified to name the drug in its body text. — SOURCE EDITION: Plumb's Veterinary Drug Handbook — ISBN 9781394172207, https://openlibrary.org/isbn/9781394172207; Withrow and MacEwen's Small Animal Clinical Oncology — ISBN 9781437723625, https://openlibrary.org/isbn/9781437723625 |
Every held source for this drug and species, as printed. Where they differ, both are shown — the choice is yours, not ours.
| Dose (mg/kg) | Route | Source | As printed |
|---|---|---|---|
| 50 | PO | Papich Saunders Handbook of Veterinary Drugs, 4th edp.415 | • 50 mg/kg PO once daily, 3 days/ • 25 mg/kg PO once daily, 3 days/ |
| 25 | PO | Papich Saunders Handbook of Veterinary Drugs, 4th edp.415 | • 50 mg/kg PO once daily, 3 days/ • 25 mg/kg PO once daily, 3 days/ |
Figures are transcribed from the cited page or table of each held edition and are shown for reference only. They are not dose recommendations, they do not feed the calculator, and none has been reviewed by a veterinarian.
Need the exact dose for your patient?
These ranges are per kg. Enter your dog's weight to get the precise dose and draw-up volume — unit and concentration math done for you.
Inhibits ribonucleotide reductase, blocking conversion of ribonucleotides to deoxyribonucleotides. S-phase specific. Reduces elevated cell counts rapidly.
Myelosuppression is dose-dependent and predictable. Monitor CBC weekly initially. Megaloblastic changes expected. Used for polycythemia vera, CML, and meningioma in dogs and cats.
Species-specific contraindications and adverse-reaction reports for dogs may differ from canine / feline reference data — consult the primary citations listed with each rule.
Hydroxyurea dose range in dogs, with cited source references: PO 50–60 mg/kg q24h initially, then taper to every other day. Reference ranges from cited sources — verify against current literature before clinical use.
Documented routes for Hydroxyurea in dogs: PO.
Cited course lengths for Hydroxyurea in dogs include: Chronic use; titrate based on CBC. Duration depends on the indication — match it to the specific dose rule in the table above.
Hydroxyurea is indicated in dogs for: Polycythemia vera / chronic myelogenous leukaemia.
These are general warnings for Hydroxyurea across species; consult the dog dosing table above for species-specific guidance. Myelosuppression is dose-dependent and predictable. Monitor CBC weekly initially. Megaloblastic changes expected. Used for polycythemia vera, CML, and meningioma in dogs and cats.
Why a species-specific page? Hydroxyurea pharmacokinetics differ across species: dose ranges, intervals, and route preferences are not interchangeable. Cross-extrapolation from canine doses is unsafe in dogs — the rules above are the citations specific to this species, not generic recommendations.
Sourced from published veterinary references; awaiting credentialed clinical reviewer. See our editorial process. Reference only — not veterinary advice.